LAVANID
Wound Irrigation Solutions
The safe solution for chronic and acute wounds
- excellent tissue tolerability
- the preparation of choice for chronic and very sensitive wounds
- for repeated and long-term wound treatment
- suitable for intraoperative use
- suitable for negative pressure wound therapy (NPWT)
Product description
LAVANID® 1/2 solutions are sterile, iso-osmotic wound irrigation solutions based on Ringer’s
solution with 0.02% or 0.04% polyhexanide as preservative. Polyhexanide prevents the growth of microorganisms in wound dressings and in the solution.
LAVANID® 1/2 Wound Irrigation Solutions are isotonic. The use of an isotonic solution
prevents swelling of the skin and irritation of the wound area, as there is no exchange of fluid or electrolytes with the body’s own secretions. Their suitability for wound management, as reported in the literature,¹ and the high tissue tolerability of LAVANID® 1/2 are not least based upon this fact.
Polyhexanide reduces the surface tension of the solution. This tenside-like effect supports the
cleansing of the wound. The irrigation solution is able to reach the tissues better and more
effectively.
Composition
Ringer’s solution (isotonic electrolyte solution comprising sodium chloride, potassium chloride, calcium chloride dihydrate, water for injection), macrogol, polyhexanide 0.02 % (LAVANID® 1) or polyhexanide 0.04 % (LAVANID® 2).
Shelf life:
Use within 2 months of first opening.
Indications for use
LAVANID® 1/2 Wound Irrigation Solutions are
suitable for local irrigation and cleansing of both acute and chronic wounds as well as for intraoperative use. In addition, LAVANID® 1/2 Wound Irrigation Solution can be used to moisten cloths, tamponades and bandages.
Application LAVANID® 1/2
Pouring out the solution with screw top.
Remove the aluminium foil and disinfect the spike insertion area.
Insert the spike*.
Application using the spike*
Bottle with inserted spike* ready for aseptic pouring.
*The spike shown is not included in the scope of delivery.
Literature
- Kramer et al., ZfW 2004; 3: 110-120, bestätigt durch Dissemond et al., ZfW, 2009; 1: 20-26; zuletzt bestätigt durch Kramer et al., Skin Pharmacol Physiol; 2018;31:28–58
- Kallenberger et al., Hyg. Med.; 1991;16: 383-395.
